NCT Number: NCT05032040
Phase: Phase 2
Trial Summary: This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Xencor, Inc.
Acronym:
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives